What is Zevra Therapeutics, Inc.'s EV / EBITDA?

Zevra Therapeutics, Inc. (ZVRA) reported EV / EBITDA of 171.7× in Q1 2026.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Zevra Therapeutics, Inc. ZVRA EV / EBITDA

EV / EBITDA at other companies

BioMarin PharmaceuticalsBMRN

21.1×+2.8×

XER

Xeris Biopharma Holdings, Inc.XERS

30.8×—

Eton Pharmaceuticals, Inc.ETON

525.2×—

Theravance BiopharmaTBPH

199.8×—

ANI PharmaceuticalsANIP

8.1×-16.2×

Arrowhead ResearchARWR

27.4×—

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$773.23M+56.4%

Enterprise value$678.78M+30.8%

P/E6.2×—

P/S6.3×-5.9×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Calculated from Zevra Therapeutics, Inc.’s reported figures.

enterprise value/ebitda=171.7×

Based on the most recent quarter.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s EV / EBITDA?: Zevra Therapeutics, Inc. (ZVRA) reported EV / EBITDA of 171.7× in Q1 2026.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.